{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.1","value":"4940"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"title":"Total Antibody"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"45.6","value":"0.370"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"}],"units":"Participants"}],"title":"SN-38G"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"29.2","value":"65.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"128"}],"units":"Participants"}],"title":"Total SN-38"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.2","value":"3290"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"120"}],"units":"Participants"}],"title":"Sacituzumab Govitecan-hziy (SG)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"58.5","value":"1.67"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"95"}],"units":"Participants"}],"title":"Free SN-38"}],"denoms":[{"counts":[{"groupId":"OG000","value":"128"}],"units":"Participants"}],"description":"AUC0-24 was determined for 5 analytes: total antibody, SN-38 glucuronide, total SN-38, free SN-38, and sacituzumab govitecan-hziy, a derived antibody drug conjugate (ADC) concentration. SN-38 is one of the components of sacituzumab govitecan-hziy. AUC0-24 is defined as area under the serum concentration-time curve from time 0 to 24 hours. The dose level evaluated for PK analysis was 10 mg/kg.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants included adults with the following tumor types:\n\ncervical cancer, colorectal cancer, endometrial cancer, epithelial ovarian cancer, esophageal cancer, gastric adenocarcinoma, glioblastoma multiforme, head and neck cancers- squamous cell, hepatocellular carcinoma, hormone-refractory prostate cancer, metastatic, non-small-cell lung cancer, pancreatic ductal adenocarcinoma, renal cell cancer, small-cell lung cancer, non-triple-negative breast cancer, triple-negative breast cancer, and metastatic urothelial cancer.\n\nAll participants received SG 10 mg/kg of body weight by IV infusion on Days 1 and 8 of a 21-day treatment cycle.","id":"OG000","title":"SG 10 mg/kg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Participants with epithelial cancer that involved any one of the following with available data were analyzed: cervical cancer, colorectal cancer, endometrial cancer, epithelial ovarian cancer, esophageal cancer, gastric adenocarcinoma, glioblastoma multiforme, head \\& neck cancers- squamouse cell, hepatocellular carcinoma, hormone-refractory prostate cancer, metastatic, non-small-cell lung cancer, pancreatic ductal adenocarcinoma, renal cell cancer, small-cell lung cancer, non TNBC, TNBC and mUC.","reportingStatus":"POSTED","timeFrame":"Cycle 1: Preinfusion, 30 minutes and 3-4 hours post infusion, then 1 day, 2 days, 3 days, and 7 days later (1 Cycle = 21 days). Infusion duration: 3 hours (± 30 minutes) for 1st infusion; 1-2 hour (± 30 minutes) for subsequent infusions","title":"PK Parameter: AUC0-24 of Total Antibody, SN-38 Glucuronide, Total SN-38, Sacituzumab Govitecan-hziy, and Free SN-38","type":"SECONDARY","unitOfMeasure":"microgram*hour per liter"}